All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Lepu Biopharma's Vebecotamab wins Chinese NMPA approval for recurrent/metastatic nasopharyngeal carcinoma, targeting EGFR pathway
Antibody-drug conjugate, cancer, EGFR-targeted ADC, nasopharyngeal carcinoma, EGFR target - Read more

THE GOOD
Business Development & Partnerships

Mycenax, RIN Institute license VLK linker technology for global ADC development services
Licensing deal, oncology, antibody, manufacturing, CDMO services - Read more

Nanobiotix receives $71M lifeline in non-dilutive capital from Healthcare Royalty
Cancer, royalty financing, radiotherapy, clinical-stage - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Vesper Bio reports positive Ph1b/2a results for VES001 targeting sortilin in frontotemporal degeneration
Small molecule, neurological, frontotemporal degeneration, progranulin, sortilin inhibitor - Read more

Genentech's Gazyva (obinutuzumab) meets Ph3 endpoints targeting CD20 for systemic lupus erythematosus treatment
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, CD20 target, B cell depletion - Read more

THE GOOD
Earnings & Finances

Gilead's long-acting HIV PrEP drug Yeztugo generates $54M sales since June launch
Injectable formulation, HIV/infectious disease, financial, operational - Read more

AbbVie's Skyrizi and Rinvoq sales surge 46% and 34% respectively in Q3 earnings
Monoclonal antibody, autoimmune, financial, revenue impact - Read more

Bristol Myers Squibb and Merck & Co. quarterly results spotlight new drug launches amid mixed performance expectations
PD-1 inhibitor, oncology, financial, strategic - Read more

THE GOOD
Fundraises

Maxvax Biotechnology raises $58M Series D, advancing shingles and RSV vaccine trials
Vaccine development, infectious disease, clinical-stage, manufacturing - Read more

Helex raises $3.5M Seed, developing targeted LNP therapeutics for genetic kidney diseases
Gene therapy, rare disease, AI-driven, platform technology - Read more

Savara raises $149.5M public offering, rare respiratory diseases focused biopharmaceutical company
Rare respiratory diseases, clinical-stage, autoimmune, recombinant protein therapy - Read more

Arcus Biosciences raises $250M public offering, cancer/inflammatory disease drug development
Clinical-stage, oncology, autoimmune, combination therapies - Read more

Corbus Pharmaceuticals raises $75M public offering, oncology and obesity drug development
Oncology, obesity, clinical-stage - Read more

THE GOOD
Strategic Plans

Gilead seeks deals across liver, oncology, virology after $4.3B CymaBay acquisition success with Livdelzi
Cell therapy, oncology, strategic, major transaction, revenue impact - Read more

THE BAD
Earnings & Finances

Illumina Q3 revenue flat at $1.08B amid China export ban but grows 2% excluding China
DNA sequencing technology, operational, financial, regulatory - Read more

THE BAD
Lawsuits

Pfizer sues Metsera, Novo Nordisk to enforce buyout deal amid obesity drug developer bidding war
Weight loss therapy, metabolic disease, strategic, major transaction - Read more

THE BAD
Regulatory

AAP declines to recommend leucovorin for autism treatment despite FDA-GSK Wellcovorin authorization efforts
Small molecule, neurological, regulatory, strategic - Read more

HRSA approves eight drugmaker 340B rebate models despite hospital opposition
Prescription drugs, drug pricing, regulatory, operational, financial - Read more

THE UGLY
Regulatory

FDA biologics center faces exodus as director Prasad's leadership creates mistrust, retaliation fears
Biologics, regulatory, operational, strategic - Read more [Paywall]

FDA drug chief Tidmarsh resigns amid investigation over complaint from healthcare investor Tang
Regulatory, strategic, operational, competitive - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here